West's Points: Evolving Issues With ALK Rearrangements

H. Jack West, MD
Published: Thursday, Jun 03, 2010

I thought I would take a moment to talk about what I am finding in regard to anaplastic lymphoma kinase (ALK) rearrangements seen in approximately 4% of patients with non–small cell lung cancer, as reviewed by Shaw et al in a September 2009 issue of the Journal of Clinical Oncology. The Plenary Session at the upcoming American Society of Clinical Oncology annual meeting in June will feature a presentation on a small subset of patients with ALK rearrangements. Crizotinib, also known as PF-02341066, is a first-in-class experimental ALK inhibitor. In early trials, it has produced a high rate of response in patients with ALK rearrangements. Our center is participating in two of the early Pfizer-sponsored trials for patients with an ALK rearrangement as defined by testing at a central laboratory arising from the collaboration between Abbott and Pfizer. One is a phase III trial randomizing patients to second-line therapy with pemetrexed or docetaxel compared with crizotinib. The other is a companion single-arm phase II study of crizotinib for more extensively treated patients or for patients who were randomized to chemotherapy in the phase III second-line trial.



Several patients are finding their way to me after having their tumor tissue tested for ALK rearrangement at a laboratory that is performing this work outside of an official trial capacity. I have encountered patients who had their tumor tissue tested commercially through the pathology departments at the University of Colorado and Massachusetts General Hospital (MGH), and I understand that Genzyme is now offering ALK testing. Other laboratories are rapidly working toward offering testing. Previously, testing for ALK was available only through the oncology centers conducting the crizotinib trials. While this barrier to testing has been knocked down in the past few months, new challenges have emerged. 



Although patients can have tumor tissue tested at an outside laboratory and found to be positive for an ALK rearrangement, this will not satisfy testing requirements to get a patient into a crizotinib trial. Tissue must still be sent to the central laboratory. Some patients will have run out of available tissue after their preliminary ALK test and may need another biopsy to obtain tissue for the official ALK test at the central laboratory—the one that counts. This even applies to patients whose tumor tissue was tested at MGH, which was the reference laboratory before Abbott got its own laboratory up and running earlier this year.



I have had my first patient who tested positive at an outside laboratory and then received a result of “negative for ALK rearrangement” for tissue tested at the Abbott laboratory. It is unclear whether this represents heterogeneity of tumor tissue or an error in technique for testing at either laboratory. The limited studies to assess heterogeneity of epidermal growth factor receptor (EGFR) mutations have certainly established that there is a disturbing precedent of tissue heterogeneity for the occurrence of an EGFR mutation within a tumor. It would not surprise me if different areas of cancer in the same person, or even different areas of the same tumor, might produce different results in terms of detecting ALK rearrangements. Yet, the only way a patient can be treated with crizotinib is to have a positive test for an ALK rearrangement at the central laboratory. I cringe to think that this lack of concordance might be a recurring observation. I have learned the hard way that the only thing worse than telling patients hopeful about crizotinib that they do not have an ALK rearrangement is telling patients that have come to my center from another state to enroll in a crizotinib trial that they tested negative at the central laboratory after testing positive initially. 




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 18th Annual International Lung Cancer Congress®Oct 31, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing Chemotherapy Induced Nausea and VomitingOct 31, 20182.0
Publication Bottom Border
Border Publication
x